The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1245 Weight Loss articles
GLP-1 agonists, initially for blood sugar and weight loss, are now investigated for their impact on sexual function. Studies reveal diverse effects on libido, influenced by various factors. Some experience increased libido, while others report a decline.
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
Indian drugmakers are modifying their pricing strategies for weight-loss injections after Novo Nordisk decreased the price of Wegovy. Generic companies are now reassessing their launch prices due to this shift. Competition is anticipated to lower prices in the GLP-1 market.
The federal government has negotiated lower prices for 15 widely used medications covered by Medicare, potentially cutting spending by 44%. While Medicare enrollees are protected by a cap on drug costs, the new prices could save millions enrolled in the Part D pharmaceutical plan a total of about $685 million.
Lizzo has voiced her concerns regarding the current weight-loss culture and its impact on plus-size women. She believes that the rise of weight-loss drugs like Ozempic is leading to the 'erasure' of plus-size representation.
Research suggests a daily GLP-1 pill could be a promising option for weight management. The results indicate a potential alternative to injectable weight loss treatments. Health tracking apps like Shotlee can help monitor progress.
Scientists are striving to develop weight-loss drugs that don't cause nausea, a common side effect of medications like Wegovy and Zepbound. Research is focused on targeting specific brain regions to suppress appetite effectively without triggering nausea or other adverse effects.
A recent study has provided real-world evidence of the cardiovascular benefits of tirzepatide, a dual GLP-1 and GIP receptor agonist. The research compared tirzepatide to semaglutide and sitagliptin, finding similar heart protection.
Gemma Collins stopped taking Mounjaro due to experiencing severe pain, which she initially feared was connected to the weight loss medication. After a break, she has decided to resume treatment through microdosing to minimize potential side effects while continuing her weight loss journey.
